OMass Therapeutics

Executive Summary

OMass Therapeutics is a UK-based biotechnology company founded in 2016 that specializes in discovering and developing small molecule drugs targeting membrane protein complexes and intracellular assemblies, with a focus on immunological and neurological diseases. The company's proprietary platform integrates native mass spectrometry, biochemistry, and custom chemistry to study targets in their native biological ecosystems, enabling the modulation of highly validated but challenging targets. By addressing difficult-to-drug protein complexes, OMass aims to unlock new therapeutic opportunities in areas of high unmet need. The company has raised significant funding from investors and has established partnerships, though specific financial details are not publicly disclosed. OMass is positioned as a leader in the application of native mass spectrometry for drug discovery, with a pipeline that is advancing towards clinical development.

Upcoming Catalysts (preview)

• 2025Series C Funding Round80% success
• 2026Lead Program IND Filing50% success
• 2025Major Pharmaceutical Partnership60% success